0002000324-24-002556.txt : 20240830
0002000324-24-002556.hdr.sgml : 20240830
20240829173237
ACCESSION NUMBER: 0002000324-24-002556
CONFORMED SUBMISSION TYPE: N-PX
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240630
FILED AS OF DATE: 20240830
EFFECTIVENESS DATE: 20240830
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Affinity Asset Advisors, LLC
CENTRAL INDEX KEY: 0001773195
ORGANIZATION NAME:
IRS NUMBER: 821567490
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: N-PX
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-20754
FILM NUMBER: 241265008
BUSINESS ADDRESS:
STREET 1: 767 THIRD AVENUE
STREET 2: 15TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 917-826-4533
MAIL ADDRESS:
STREET 1: 767 THIRD AVENUE
STREET 2: 15TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
N-PX
1
primary_doc.xml
N-PX
IM
LIVE
0001773195
XXXXXXXX
false
false
06/30/2024
YEAR
2024
Affinity Asset Advisors, LLC
646-481-8008
767 THIRD AVENUE
15th Floor
New York
NY
10017
Jonathan Chu
767 THIRD AVENUE
15th Floor
New York
NY
10017
INSTITUTIONAL MANAGER VOTING REPORT
028-20754
000312788
549300307G5AWN6LYD87
N
0
0
Affinity Asset Advisors, LLC
Jonathan Chu
Jonathan Chu
Chief Compliance Officer
08/27/2024
PROXY VOTING RECORD
2
testwednesdaynew2.xml
ALKERMES PLC
G01767105
IE00B56GVS15
05/31/2024
To approve, in a non-binding, advisory vote, the compensation of
the Company's named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
19815
0
FOR
19815
FOR
ALKERMES PLC
G01767105
IE00B56GVS15
05/31/2024
To approve, in a non-binding, advisory vote, the frequency of future
advisory votes on the compensation of the Company's named
executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
19815
0
1 YEAR
19815
FOR
ANTERIS TECHNOLOGIES LTD
Q0425C102
AU0000088841
05/29/2024
ADOPTION OF THE REMUNERATION REPORT
SECTION 14A SAY-ON-PAY VOTES
ISSUER
90000
0
FOR
90000
FOR
APELLIS PHARMACEUTICALS INC.
03753U106
US03753U1060
06/05/2024
Approval of an advisory vote on executive compensation
SECTION 14A SAY-ON-PAY VOTES
ISSUER
62460
0
FOR
62460
FOR
ARCELLX, INC.
03940C100
US03940C1009
05/24/2024
To approve, on an advisory basis, the compensation of the named
executive officers identified in the 2023 Summary Compensation
Table in the "Executive Compensation" section of the proxy
statement (the "Say-on-Pay Vote")
SECTION 14A SAY-ON-PAY VOTES
ISSUER
296250
0
FOR
296250
FOR
ARCELLX, INC.
03940C100
US03940C1009
05/24/2024
To approve, on an advisory basis, the frequency of future Say-on-
Pay Votes
SECTION 14A SAY-ON-PAY VOTES
ISSUER
296250
0
1 YEAR
296250
FOR
ASTRIA THERAPEUTICS, INC.
04635X102
US04635X1028
06/05/2024
The approval, by non-binding advisory vote, of our executive
compensation
SECTION 14A SAY-ON-PAY VOTES
ISSUER
268300
0
FOR
268300
FOR
AUTOLUS THERAPEUTICS PLC
05280R100
US05280R1005
06/28/2024
To approve the Directors' remuneration report set out on pages 18
to 44 (inclusive) of the 2023 Annual Report and Accounts.
SECTION 14A SAY-ON-PAY VOTES
ISSUER
3168454
0
FOR
3168454
FOR
AVROBIO, INC.
05455M100
US05455M1009
06/11/2024
The Executive Compensation Arrangements Proposal - To
approve, on a non-binding advisory vote basis, compensation that
will or may become payable by AVROBIO to its named executive
officers in connection with the merger, each as described in the
accompanying proxy statement/prospectus.
SECTION 14A SAY-ON-PAY VOTES
ISSUER
650000
0
FOR
650000
FOR
AXSOME THERAPEUTICS, INC.
05464T104
US05464T1043
06/07/2024
To approve, by non-binding advisory vote, the compensation of our
named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
42866
0
FOR
42866
FOR
BEIGENE LTD
07725L102
US07725L1026
06/05/2024
THAT, on a non-binding, advisory basis, the compensation of the
Company's named executive officers, as disclosed in the Proxy
Statement, be and is hereby approved
SECTION 14A SAY-ON-PAY VOTES
ISSUER
26745
0
FOR
26745
FOR
BEIGENE LTD
07725L102
US07725L1026
06/05/2024
THAT, on a non-binding, advisory basis, the frequency of future
advisory votes on the compensation of the Company's named
executive officers will be held at the frequency hereby approved
SECTION 14A SAY-ON-PAY VOTES
ISSUER
26745
0
1 YEAR
26745
FOR
BOSTON SCIENTIFIC CORPORATION
101137107
US1011371077
05/02/2024
To approve, on a non-binding, advisory basis, the compensation of
our named executive officers.
SECTION 14A SAY-ON-PAY VOTES
ISSUER
13416
0
FOR
13416
FOR
CELLDEX THERAPEUTICS, INC.
15117B202
US15117B2025
06/13/2024
To approve, on an advisory basis, the compensation of the
Company's Named Executive Officers as disclosed in the Proxy
Statement
SECTION 14A SAY-ON-PAY VOTES
ISSUER
177906
0
FOR
177906
FOR
CENTESSA PHARMACEUTICALS PLC
152309100
US1523091007
06/25/2024
To receive and approve on an advisory basis the Company's U.K.
statutory directors' remuneration report for the financial year ended
December 31, 2023, which is set forth as Annex A to the attached
proxy statement
SECTION 14A SAY-ON-PAY VOTES
ISSUER
776674
0
FOR
776674
FOR
CEREVEL THERAPEUTICS HOLDINGS, INC.
15678U128
US15678U1280
02/16/2024
To approve, on a non-binding, advisory basis, certain
compensation that will or may be paid or become payable to
Cerevel's named executive officers that is based on or otherwise
relates to the Merger
SECTION 14A SAY-ON-PAY VOTES
ISSUER
750000
0
FOR
750000
FOR
CHINOOK THERAPEUTICS, INC.
16961L106
US16961L1061
08/02/2023
To consider and vote upon the proposal to approve, on an advisory
(non-binding) basis, certain compensation that may be paid or
become payable to Company's named executive officers in
connection with the Merger
SECTION 14A SAY-ON-PAY VOTES
ISSUER
321015
0
FOR
321015
FOR
COMPASS PATHWAYS PLC
20451W101
US20451W1018
05/09/2024
To receive and approve on an advisory basis the Company's U.K.
statutory directors' remuneration report for the year ended 31
December 2023
SECTION 14A SAY-ON-PAY VOTES
ISSUER
741141
0
FOR
741141
FOR
COMPASS PATHWAYS PLC
20451W101
US20451W1018
05/09/2024
To approve, on a non-binding, advisory basis, the compensation of
the Company's named executive officers for the year ended 31
December 2023
SECTION 14A SAY-ON-PAY VOTES
ISSUER
741141
0
FOR
741141
FOR
CRINETICS PHARMACEUTICALS INC.
22663K107
US22663K1079
06/07/2024
To consider and vote upon, on an advisory basis, the
compensation of the Company's named executive officers as
disclosed in the proxy statement pursuant to the compensation
disclosure rules of the Securities and Exchange Commission
SECTION 14A SAY-ON-PAY VOTES
ISSUER
388561
0
FOR
388561
FOR
ESTABLISHMENT LABS HOLDINGS INC.
G31249108
VGG312491084
05/24/2024
To approve, on an advisory basis, the compensation of our named
executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
105341
0
FOR
105341
FOR
GERON CORPORATION
374163103
US3741631036
05/09/2024
To approve, on an advisory basis, the compensation of the
company's named executive officers, as disclosed in the
company's proxy statement
SECTION 14A SAY-ON-PAY VOTES
ISSUER
126832
0
FOR
126832
FOR
HOMOLOGY MEDICINES, INC.
438083107
US4380831077
03/15/2024
To approve on an advisory, non-binding basis certain
compensation arrangements for Homology's named executive
officers in connection with the Merger
SECTION 14A SAY-ON-PAY VOTES
ISSUER
115110
0
FOR
115110
FOR
IMMUNOGEN, INC.
45253H101
US45253H1014
01/31/2024
To consider and vote on the proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to
ImmunoGen's named executive officers that is based on or
otherwise relates to the Merger Agreement and the transactions
contemplated by the Merger Agreement (the ''Compensation
Proposal'')
SECTION 14A SAY-ON-PAY VOTES
ISSUER
700750
0
FOR
700750
FOR
IMMUNOVANT INC
45258J102
US45258J1025
08/21/2023
To approve, on a non-binding, advisory basis, the compensation of
our named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
259998
0
FOR
259998
FOR
INARI MEDICAL, INC.
45332Y109
US45332Y1091
04/24/2024
To approve, on an advisory basis, the compensation of our named
executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
14217
0
FOR
14217
FOR
KALVISTA PHARMACEUTICALS, INC.
483497103
US4834971032
09/26/2023
Approve, on a non-binding advisory basis, of the compensation
paid by us to our named executive officers as disclosed in this
proxy statement
SECTION 14A SAY-ON-PAY VOTES
ISSUER
0
0
FOR
0
FOR
KEZAR LIFE SCIENCES, INC.
49372L100
US49372L1008
06/18/2024
Advisory vote on the compensation paid to our named executive
officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
494018
0
FOR
494018
FOR
KEZAR LIFE SCIENCES, INC.
49372L100
US49372L1008
06/18/2024
Preferred frequency of the advisory vote on the compensation paid
to our named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
494018
0
1 YEAR
494018
FOR
KRYSTAL BIOTECH, INC.
501147102
US5011471027
05/17/2024
Approval of the compensation of the Company's named executive
officers, on a non-binding, advisory basis
SECTION 14A SAY-ON-PAY VOTES
ISSUER
9509
0
FOR
9509
FOR
KURA ONCOLOGY, INC.
50127T109
US50127T1097
06/05/2024
Approval, on an advisory basis, of the compensation of our named
executive officers during the year ended December 31, 2023
SECTION 14A SAY-ON-PAY VOTES
ISSUER
346954
0
FOR
346954
FOR
MADRIGAL PHARMACEUTICALS INC.
558868105
US5588681057
06/25/2024
Advisory vote to approve executive compensation
SECTION 14A SAY-ON-PAY VOTES
ISSUER
31315
0
FOR
31315
FOR
MERSANA THERAPEUTICS, INC.
59045L106
US59045L1061
06/11/2024
To approve, on a non-binding, advisory basis, the compensation of
the Company's named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
750000
0
FOR
750000
FOR
MIRATI THERAPEUTICS, INC.
60468T105
US60468T1051
12/13/2023
To approve, by non-binding, advisory vote, compensation that may
be paid or become payable by Mirati to its named executive
officers in connection with the Merger
SECTION 14A SAY-ON-PAY VOTES
ISSUER
427444
0
FOR
427444
FOR
MIRUM PHARMACEUTICALS, INC.
604749101
US6047491013
06/05/2024
To approve, on an advisory basis, the compensation of the
Company's named executive officers, as disclosed in the Proxy
Statement
SECTION 14A SAY-ON-PAY VOTES
ISSUER
47109
0
FOR
47109
FOR
MIRUM PHARMACEUTICALS, INC.
604749101
US6047491013
06/05/2024
To indicate, on an advisory basis, the preferred frequency of
stockholder advisory votes on the compensation of the Company's
named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
47109
0
1 YEAR
47109
FOR
MORPHIC HOLDING, INC.
61775R105
US61775R1059
06/04/2024
To approve, on a non-binding advisory basis, the compensation
paid to the Company's Named Executive Officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
203085
0
FOR
203085
FOR
NURIX THERAPEUTICS, INC.
67080M103
US67080M1036
05/20/2024
To approve, on a non-binding advisory basis, the compensation of
the Company's named executive officers as disclosed in the proxy
statement
SECTION 14A SAY-ON-PAY VOTES
ISSUER
449260
0
FOR
449260
FOR
NUVALENT, INC.
670703107
US6707031075
06/12/2024
To approve, on an advisory basis, the compensation paid to our
named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
91168
0
FOR
91168
FOR
NUVALENT, INC.
670703107
US6707031075
06/12/2024
To approve, on an advisory basis, the frequency of future advisory
votes to approve the compensation paid to our named executive
officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
91168
0
1 YEAR
91168
FOR
REATA PHARMACEUTICALS, INC.
75615P103
US75615P1030
09/21/2023
To approve, on an advisory, non-binding basis, compensation that
will or may be paid or become payable to Reata's named executive
officers in connection with the Merger contemplated by the Merger
Agreement
SECTION 14A SAY-ON-PAY VOTES
ISSUER
0
0
FOR
0
FOR
REGENXBIO INC.
75901B107
US75901B1070
05/31/2024
To approve, on an advisory basis, the compensation paid to the
Company's named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
27608
0
FOR
27608
FOR
REZOLUTE, INC.
76200L309
US76200L3096
05/16/2024
To approve, by a non-binding advisory vote, the compensation of
the Company's named executive officers as disclosed in the
Executive Compensation section of the proxy Statement
SECTION 14A SAY-ON-PAY VOTES
ISSUER
624990
0
FOR
624990
FOR
SAVARA INC.
805111101
US8051111016
06/06/2024
To approve, on an advisory basis, the compensation of our named
executives
SECTION 14A SAY-ON-PAY VOTES
ISSUER
715256
0
FOR
715256
FOR
SPRINGWORKS
THERAPEUTICS INC
85205L107
US85205L1070
05/16/2024
Non-binding advisory vote on executive compensation
SECTION 14A SAY-ON-PAY VOTES
ISSUER
38669
0
FOR
38669
FOR
SPYRE THERAPEUTICS INC.
00773J202
US00773J2024
05/13/2024
To approve, on a non-binding, advisory basis, the compensation of
the Company's named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
171708
0
FOR
171708
FOR
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
881624209
US8816242098
06/06/2024
To approve, on a non-binding advisory basis, The compensation
for Teva's named Executive Officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
1141212
0
FOR
1141212
FOR
TEVA PHARMACEUTICAL
INDUSTRIES LIMITED
881624209
US8816242098
06/06/2024
To recommend, on a non-binding advisory basis, To hold a non-
binding advisory vote to approve the compensation for Teva's
named Executive Officers every one, two or three years
SECTION 14A SAY-ON-PAY VOTES
ISSUER
1141212
0
1 YEAR
1141212
FOR
TRAVERE THERAPEUTICS, INC.
89422G107
US89422G1076
05/08/2024
To approve, on an advisory basis, the compensation of the
Company's named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
52733
0
FOR
52733
FOR
VAXCYTE, INC.
92243G108
US92243G1085
06/06/2024
Approval, on a non-binding, advisory basis, of the compensation of
the Company's named executive officers.
SECTION 14A SAY-ON-PAY VOTES
ISSUER
75036
0
FOR
75036
FOR
VERONA PHARMA PLC
925050106
US9250501064
04/26/2024
To receive and approve, as a non-binding advisory resolution, the
U.K. statutory Directors' Remuneration Report for the year ended
31 December 2023
SECTION 14A SAY-ON-PAY VOTES
ISSUER
412995
0
FOR
412995
FOR
VERONA PHARMA PLC
925050106
US9250501064
04/26/2024
To approve, on an advisory (non-binding) basis, the compensation
of the Company's named executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
412995
0
FOR
412995
FOR
VIKING THERAPEUTICS INC
92686J106
US92686J1060
05/21/2024
To approve, on an advisory basis, the compensation of our named
executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
33268
0
FOR
33268
FOR
XENON PHARMACEUTICALS INC
98420N105
CA98420N1050
06/04/2024
Compensation of Named Executive Officers: Approve, on an
advisory basis, the compensation of the Corporation's named
executive officers
SECTION 14A SAY-ON-PAY VOTES
ISSUER
772816
0
FOR
772816
FOR
ZEALAND PHARMA A/S
K9898X127
DK0060257814
03/20/2024
PROPOSAL FROM THE BOARD OF DIRECTORS TO APPROVE
THE COMPANY'S REMUNERATION REPORT
SECTION 14A SAY-ON-PAY VOTES
ISSUER
140027
0
FOR
140027
FOR